Fig. 1 |. Recurrent wild-type GBM is associated with tenascin C.

a, Representative image of the multiplex immunohistochemistry analysis of primary and recurrent GBM patient tissue samples (four patients) stained for tenascin C (TNC) in yellow and pMLC2 in red (Nam cohort). Scale bar, 50 μm. b, Quantification of cells expressing TNC in matched primary and recurrent GBM patient samples from a (n = 4 patients; P = 0.047 using a two-sided paired t-test). c, Correlation plot of percent cells expressing TNC versus pMLC2 from eight human GBM samples using Spearman correlation. d, Kaplan–Meier survival analysis of Rembrandt data for TNC based on its expression level across all glioma samples (n = 214 GBM, 66 oligodendroglioma and 145 astrocytoma patients; P value calculated using two-sided logrank test). e, Kaplan–Meier analysis of TCGA GBM data (n = 401 patients) showing the survival probability of patients with high versus low EMT gene expression (see gene list in Supplementary Table 1) in glioma. P value calculated using logrank test. f, TCGA data analysed for the expression level of TNC in human proneural (Pro; n = 57 patients) and mesenchymal (Mes; n = 58 patients) GBM. Mean ± s.e.m.; ***P = 4.27 × 10⁻⁸ using two-sided Mann–Whitney U-test.